NASDAQ:NMTR

9 Meters Biopharma Stock Forecast, Price & News

$0.72

-0.03 (-4.00%)

(As of 01/27/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.72
▼
$0.77
50-Day Range: $0.72
▼
$1.09
52-Week Range: $0.72
▼
$2.26

Volume: 746,328 shs
Average Volume: 1.33 million shs
Market Capitalization: $184.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: -0.23

30 days | 90 days | 365 days | Advanced Chart

Receive NMTR News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

About 9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

9 meters Bio secures new U.S. patent for NM-102 + immune checkpoint inhibitors
January 24, 2022 | seekingalpha.com

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
January 24, 2022 | finance.yahoo.com

Raleigh public company adds former Biogen exec to C-suite
January 21, 2022 | finance.yahoo.com

9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
January 18, 2022 | finance.yahoo.com

9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
January 4, 2022 | finance.yahoo.com

9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
January 3, 2022 | finance.yahoo.com

9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
December 15, 2021 | finance.yahoo.com

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)
November 18, 2021 | finance.yahoo.com

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
November 15, 2021 | finance.yahoo.com

9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
November 10, 2021 | finance.yahoo.com

9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
November 9, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NMTR
Previous Symbol
CUSIP: N/A
CIK: 1551986
Web: www.9meters.com
Phone: (919) 275-1933
Fax: N/A
Employees: 12
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.16 per share
Price / Book: 4.50

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: $-61.50 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.84%
Return on Assets: -63.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.76
Quick Ratio: 7.76

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 255,668,000
Free Float: 248,509,000
Market Cap: $184.16 million
Optionable: Optionable

Company Calendar

Last Earnings: 11/15/2021
Today: 1/28/2022
Next Earnings (Estimated): 3/28/2022
Fiscal Year End: 12/31/2022

MarketRank^™

Overall MarketRank^™

2.16 out of 5 stars

Medical Sector

446th out of 1,417 stocks

Pharmaceutical Preparations Industry

201st out of 683 stocks

3.5 Analyst's Opinion

Consensus Rating
9 Meters Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, 9 Meters Biopharma has a forecasted upside of 594.2% from its current price of $0.72.
Amount of Analyst Coverage
9 Meters Biopharma has received no research coverage in the past 90 days.

5.0 Community Rank

Outperform Votes
9 Meters Biopharma has received 32 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
9 Meters Biopharma has received 7 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
9 Meters Biopharma has received 82.05% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about 9 Meters Biopharma and other stocks. Vote “Outperform” if you believe NMTR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NMTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
9 Meters Biopharma does not currently pay a dividend.
Dividend Growth
9 Meters Biopharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 9 Meters Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $118,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.80% of the stock of 9 Meters Biopharma is held by insiders.
Percentage Held by Institutions
Only 28.40% of the stock of 9 Meters Biopharma is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for 9 Meters Biopharma are expected to grow in the coming year, from ($0.15) to ($0.11) per share.
Price to Book Value per Share Ratio
9 Meters Biopharma has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

9 Meters Biopharma (NASDAQ:NMTR) Frequently Asked Questions

Is 9 Meters Biopharma a buy right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 9 Meters Biopharma stock.
View analyst ratings for 9 Meters Biopharma or view top-rated stocks.
When is 9 Meters Biopharma's next earnings date?: 9 Meters Biopharma is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for 9 Meters Biopharma.
How were 9 Meters Biopharma's earnings last quarter?: 9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.
View 9 Meters Biopharma's earnings history.
What price target have analysts set for NMTR?: 6 analysts have issued 1-year target prices for 9 Meters Biopharma's stock. Their forecasts range from $3.00 to $6.00. On average, they expect 9 Meters Biopharma's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 594.2% from the stock's current price.
View analysts' price targets for 9 Meters Biopharma or view top-rated stocks among Wall Street analysts.
Who are 9 Meters Biopharma's key executives?: 9 Meters Biopharma's management team includes the following people:
John Temperato, President, Chief Executive Officer & Director (LinkedIn Profile)
Sireesh Appajosyula, SVP-Corporate Development & Operations
Bethany L. Sensenig, Chief Financial & Accounting Officer
Patrick H. Griffin, Chief Medical Officer
Sarah Liu, Chief Commercial Officer
Who are some of 9 Meters Biopharma's key competitors?: Some companies that are related to 9 Meters Biopharma include Syndax Pharmaceuticals (SNDX), Kiniksa Pharmaceuticals (KNSA), Arcutis Biotherapeutics (ARQT), PMV Pharmaceuticals (PMVP), Endo International (ENDP), MacroGenics (MGNX), Tango Therapeutics (TNGX), Seres Therapeutics (MCRB), Amryt Pharma (AMYT), Edgewise Therapeutics (EWTX), Emisphere Technologies (EMIS), Gossamer Bio (GOSS), Avidity Biosciences (RNA), Stoke Therapeutics (STOK) and Design Therapeutics (DSGN).
View all of NMTR's competitors.
What other stocks do shareholders of 9 Meters Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO).
What is 9 Meters Biopharma's stock symbol?: 9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."
Who are 9 Meters Biopharma's major shareholders?: 9 Meters Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include J.W. Cole Advisors Inc. (0.02%). Company insiders that own 9 Meters Biopharma stock include Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino.
View institutional ownership trends for 9 Meters Biopharma.
Which major investors are buying 9 Meters Biopharma stock?: NMTR stock was bought by a variety of institutional investors in the last quarter, including J.W. Cole Advisors Inc.. Company insiders that have bought 9 Meters Biopharma stock in the last two years include Edward J Sitar, John Temperato, Mark A Sirgo, and Michael T Constantino.
View insider buying and selling activity for 9 Meters Biopharma or or view top insider-buying stocks.
How do I buy shares of 9 Meters Biopharma?: Shares of NMTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is 9 Meters Biopharma's stock price today?: One share of NMTR stock can currently be purchased for approximately $0.72.
How much money does 9 Meters Biopharma make?: 9 Meters Biopharma has a market capitalization of $184.16 million.
How many employees does 9 Meters Biopharma have?: 9 Meters Biopharma employs 12 workers across the globe.
What is 9 Meters Biopharma's official website?: The official website for 9 Meters Biopharma is www.9meters.com.
Where are 9 Meters Biopharma's headquarters?: 9 Meters Biopharma is headquartered at 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615.
How can I contact 9 Meters Biopharma?: 9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at (919) 275-1933 or via email at [email protected].

This page was last updated on 1/28/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

9 Meters Biopharma Stock Forecast, Price & News

About 9 Meters Biopharma

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

1.7 Company Ownership

0.6 Earnings and Valuation

9 Meters Biopharma (NASDAQ:NMTR) Frequently Asked Questions

Is 9 Meters Biopharma a buy right now?

When is 9 Meters Biopharma's next earnings date?

How were 9 Meters Biopharma's earnings last quarter?

What price target have analysts set for NMTR?

Who are 9 Meters Biopharma's key executives?

Who are some of 9 Meters Biopharma's key competitors?

What other stocks do shareholders of 9 Meters Biopharma own?

What is 9 Meters Biopharma's stock symbol?

Who are 9 Meters Biopharma's major shareholders?

Which major investors are buying 9 Meters Biopharma stock?

How do I buy shares of 9 Meters Biopharma?

What is 9 Meters Biopharma's stock price today?

How much money does 9 Meters Biopharma make?

How many employees does 9 Meters Biopharma have?

What is 9 Meters Biopharma's official website?

Where are 9 Meters Biopharma's headquarters?

How can I contact 9 Meters Biopharma?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™